Latest Breaking News On - Treating stomach - Page 1 : comparemela.com

  previously treated HER2-positive advanced gastric cancer     AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.   In the US, gastric cancer is most frequently diagnosed in the advanced stage, with only approximately 5% of patients surviving beyond five years. 1,2 Approximately one in five gastric cancers are HER2 positive. 3   The approval by the Food and Drug Administration (FDA) was based on the positive results from the randomised DESTINY-Gastric01 Phase II trial conducted in Japan and South Korea. In the trial, Enhertudemonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) and objective respo

United statesBaylor universityUnited kingdomSouth koreaDave fredricksonRonan kellyDaiichi sankyoWw caruth jrTrastuzumab deruxtecanAdrian kempAntoine yverDaiichi sankyo companyDrug administrationCharlesa sammons cancer centerOncology researchMerck co inc